Impact of compliance to oral hypoglycemic agents on short-term disability costs in an employer population

Population Health Management

Volumn 17, Issue 1, 2014, Pages 35-41

  Hagen, Susan E ^a   Wright, Douglas W ^a   Finch, Ron ^b   Talamonti, Walter J ^c   Edington, Dee W ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b National Business Group on Health   (United States)

^c FORD MOTOR COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; COSTS AND COST ANALYSIS; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; MALE; MEDICATION ADHERENCE; MICHIGAN; MIDDLE AGED; ORGANIZATIONAL CASE STUDIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84894208866     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2013.0009     Document Type: Article

References (41)

1. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 2008;31:596-615.
2. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff (Millwood) 2010;29:297-303.
3. Vojta D, De Sa J, Prospect T, Stevens S. Effective interventions for stemming the growing crisis of diabetes and prediabetes. Health Aff (Millwood) 2012;31:20-26.
4. Vijan S, Hayward RA, Langa KM. The impact of diabetes on workforce participation: Results from a national household sample. Health Serv Res 2004;39:1653-1670.
5. Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P. Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002;25: 23-29.
6. Lavigne JE, Phelps CE, Mushlin A, Lednar WM. Reductions in individual work productivity associated with type 2 diabetes mellitus. Pharmacoeconomics 2003;21:1123-1134.
7. Tunceli K, Bradley CJ, Nerenz D, Williams LK, Pladevall M, Lafata JE. The impact of diabetes on employment and work productivity. Diabetes Care 2005;28:2662-2667.
8. Skerjanc A. Sickness absence in diabetic employees. Occup Environ Med 2001;58:432-436.
9. Boles M, Pelletier B, Lynch W. The relationship between health risks and work productivity. J Occup Environ Med 2004;46:737-745.
10. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003;45:5-14.
11. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 2004;46:398-412.
12. Goetzel RZ, Ozminkowski RJ, Villagra VG, Duffy J. Return on investment in disease management: A review. Health Care Financ Rev 2005;26:1-19.
13. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28: 437-443.
14. Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004;38:1357-1362.
15. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
16. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166: 1836-1841.
17. Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16:589-600.
18. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: A literature review. Int J Clin Pract 2008;62:338-351.
19. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-530.
20. Encinosa W, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? Available at: http://www.nber.org/papers/w15691. Accessed January 29, 2013.
21. Carls GS, Roebuck C, Brennan TA, Slezak JA, Matlin OS, Gibson TB. Impact of medication adherence on absenteeism and short-term disability for five chronic diseases. J Occup Environ Med 2012;54:792-805.
22. Loeppke R, Haufle V, Jinnett K, et al. Medication adherence, comorbidities, and health risk impacts on workforce absence and job performance. J Occup Environ Med 2011;53: 595-604.
23. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12.
24. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008;11:44-47.
25. th ed. Portland, ME: JHA; 2006:34.
26. Cancer, pregnancy continue to lead disability causes for Unum. Released May 8, 2012. Available at: http://www.investors.unum.com/phoenix.zhtml?c= 112190&p=irolnewsArticle&ID=1421347&highlight=. Accessed January 29, 2013.
27. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10:144-151.
28. Health Care Cost Institute. Health care cost and utilization report: 2011. Available at: http://www.healthcostinstitute.org/files/HCCI-HCCUR2011.pdf. Accessed February 26, 2013.
29. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood) 2008;27:103-112.
30. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;16:CD000011.
31. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: A systematic review. Arch Intern Med 2007;167:540-550.
32. Agency for Healthcare Research and Quality. Closing the quality gap series: medication adherence interventions: comparative effectiveness. Available at: http://effective healthcare.ahrq.gov/index.cfm/search-for-guides- reviewsand-reports/?productid=1249&pageaction = displayproduct. Accessed January 30, 2013.
33. Gibson TB, Wang S, Kelly E, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood) 2011;30:109-117.
34. Misono AS, Cutrona SL, Choudhry NK, et al. Healthcare information technology interventions to improve cardiovascular and diabetes medication adherence. Am J Manag Care 2010;16(12 suppl HIT):SP82-SP92.
35. Collins S, Piper KB, Owens GM. The opportunity for health plans to improve quality and reduce costs by embracing primary care medical homes. Am Health Drug Benefits 2013;6:30-37.
36. Schoenthaler AM, Schwartz BS, Wood C, Stewart WF. Patient and physician factors associated with adherence to diabetes medications. Diabetes Educ 2012;38:398-407.
37. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Therap 2011;33:74-109.
38. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-2805.
39. Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet. Available at: http://www.cdc.gov/diabetes/pubs/estimates11.htm. Accessed February 26, 2013.
40. Owens DR. Stepwise intensification of insulin therapy in Type 2 diabetes management. Diabet Med 2013;30:276-288.
41. Asche CV, Bode B, Busk AK, Nair SR. The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:47-57.